Spinal muscular atrophy care in the COVID-19 pandemic era

Aravindhan Veerapandiyan; Anne M. Connolly; Richard S. Finkel; Kapil Arya; Katherine D. Mathews; Edward C. Smith; Diana Castro; Russell J. Butterfield; Julie A. Parsons; Laurent Servais; Nancy Kuntz; Vamshi K. Rao; John F. Brandsema; Eugenio Mercuri; Emma Ciafaloni

doi:10.1002/mus.26903

Spinal muscular atrophy care in the COVID-19 pandemic era

Aravindhan Veerapandiyan, Anne M. Connolly, Richard S. Finkel, Kapil Arya, Katherine D. Mathews, Edward C. Smith, Diana Castro, Russell J. Butterfield, Julie A. Parsons, Laurent Servais, Nancy Kuntz, Vamshi K. Rao, John F. Brandsema, Eugenio Mercuri, Emma Ciafaloni

Research output: Contribution to journal › Article › peer-review

31 Scopus citations

Abstract

The coronavirus disease 2019 (COVID-19) pandemic has resulted in reorganization of healthcare settings affecting the delivery of clinical care to patients with spinal muscular atrophy (SMA). There is a concern that patients with SMA may be at increased risk of manifesting severe symptoms of COVID-19. Currently approved therapies for SMA improve survival and motor function; however, their delivery requires an increased exposure to the health system and a dedicated healthcare team. In this study, we discuss consensus recommendations pertaining to care of SMA patients during the pandemic. We highlight that SMA treatments should not be perceived as elective. Decisions regarding the delay of treatments should be made with consideration of the potential risks of COVID-19 exposure and the risk of that delay. We emphasize the importance of collaborative treatment decisions between the patient, family, and healthcare provider, considering any geographic- or institution-specific policies and precautions for COVID-19.

Original language	English (US)
Pages (from-to)	46-49
Number of pages	4
Journal	Muscle and Nerve
Volume	62
Issue number	1
DOIs	https://doi.org/10.1002/mus.26903
State	Published - Jul 1 2020

Keywords

SMA
corona
epidemic
guidelines
pandemic
treatment

ASJC Scopus subject areas

Physiology
Clinical Neurology
Cellular and Molecular Neuroscience
Physiology (medical)

Access to Document

10.1002/mus.26903

Cite this

@article{da7d2c2be82349a3aa443e2a55e67dd7,

title = "Spinal muscular atrophy care in the COVID-19 pandemic era",

abstract = "The coronavirus disease 2019 (COVID-19) pandemic has resulted in reorganization of healthcare settings affecting the delivery of clinical care to patients with spinal muscular atrophy (SMA). There is a concern that patients with SMA may be at increased risk of manifesting severe symptoms of COVID-19. Currently approved therapies for SMA improve survival and motor function; however, their delivery requires an increased exposure to the health system and a dedicated healthcare team. In this study, we discuss consensus recommendations pertaining to care of SMA patients during the pandemic. We highlight that SMA treatments should not be perceived as elective. Decisions regarding the delay of treatments should be made with consideration of the potential risks of COVID-19 exposure and the risk of that delay. We emphasize the importance of collaborative treatment decisions between the patient, family, and healthcare provider, considering any geographic- or institution-specific policies and precautions for COVID-19.",

keywords = "SMA, corona, epidemic, guidelines, pandemic, treatment",

author = "Aravindhan Veerapandiyan and Connolly, {Anne M.} and Finkel, {Richard S.} and Kapil Arya and Mathews, {Katherine D.} and Smith, {Edward C.} and Diana Castro and Butterfield, {Russell J.} and Parsons, {Julie A.} and Laurent Servais and Nancy Kuntz and Rao, {Vamshi K.} and Brandsema, {John F.} and Eugenio Mercuri and Emma Ciafaloni",

note = "Publisher Copyright: {\textcopyright} 2020 Wiley Periodicals, Inc.",

year = "2020",

month = jul,

day = "1",

doi = "10.1002/mus.26903",

language = "English (US)",

volume = "62",

pages = "46--49",

journal = "Muscle and Nerve",

issn = "0148-639X",

publisher = "John Wiley and Sons Inc.",

number = "1",

}

TY - JOUR

T1 - Spinal muscular atrophy care in the COVID-19 pandemic era

AU - Veerapandiyan, Aravindhan

AU - Connolly, Anne M.

AU - Finkel, Richard S.

AU - Arya, Kapil

AU - Mathews, Katherine D.

AU - Smith, Edward C.

AU - Castro, Diana

AU - Butterfield, Russell J.

AU - Parsons, Julie A.

AU - Servais, Laurent

AU - Kuntz, Nancy

AU - Rao, Vamshi K.

AU - Brandsema, John F.

AU - Mercuri, Eugenio

AU - Ciafaloni, Emma

PY - 2020/7/1

Y1 - 2020/7/1

N2 - The coronavirus disease 2019 (COVID-19) pandemic has resulted in reorganization of healthcare settings affecting the delivery of clinical care to patients with spinal muscular atrophy (SMA). There is a concern that patients with SMA may be at increased risk of manifesting severe symptoms of COVID-19. Currently approved therapies for SMA improve survival and motor function; however, their delivery requires an increased exposure to the health system and a dedicated healthcare team. In this study, we discuss consensus recommendations pertaining to care of SMA patients during the pandemic. We highlight that SMA treatments should not be perceived as elective. Decisions regarding the delay of treatments should be made with consideration of the potential risks of COVID-19 exposure and the risk of that delay. We emphasize the importance of collaborative treatment decisions between the patient, family, and healthcare provider, considering any geographic- or institution-specific policies and precautions for COVID-19.

AB - The coronavirus disease 2019 (COVID-19) pandemic has resulted in reorganization of healthcare settings affecting the delivery of clinical care to patients with spinal muscular atrophy (SMA). There is a concern that patients with SMA may be at increased risk of manifesting severe symptoms of COVID-19. Currently approved therapies for SMA improve survival and motor function; however, their delivery requires an increased exposure to the health system and a dedicated healthcare team. In this study, we discuss consensus recommendations pertaining to care of SMA patients during the pandemic. We highlight that SMA treatments should not be perceived as elective. Decisions regarding the delay of treatments should be made with consideration of the potential risks of COVID-19 exposure and the risk of that delay. We emphasize the importance of collaborative treatment decisions between the patient, family, and healthcare provider, considering any geographic- or institution-specific policies and precautions for COVID-19.

KW - SMA

KW - corona

KW - epidemic

KW - guidelines

KW - pandemic

KW - treatment

UR - http://www.scopus.com/inward/record.url?scp=85084617607&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85084617607&partnerID=8YFLogxK

U2 - 10.1002/mus.26903

DO - 10.1002/mus.26903

M3 - Article

C2 - 32329921

AN - SCOPUS:85084617607

SN - 0148-639X

VL - 62

SP - 46

EP - 49

JO - Muscle and Nerve

JF - Muscle and Nerve

IS - 1

ER -

Spinal muscular atrophy care in the COVID-19 pandemic era

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this